| Primary |
| Product Used For Unknown Indication |
17.1% |
| Drug Use For Unknown Indication |
16.5% |
| Sarcoma |
7.9% |
| Chemotherapy |
6.4% |
| Germ Cell Cancer |
6.4% |
| T-cell Lymphoma |
5.3% |
| Rhabdomyosarcoma |
4.9% |
| B-cell Lymphoma |
4.3% |
| Ewing's Sarcoma |
4.3% |
| Neoplasm Malignant |
4.1% |
| Nasopharyngeal Cancer Recurrent |
3.8% |
| Non-hodgkin's Lymphoma |
3.0% |
| Neoplasm |
2.6% |
| Premedication |
2.4% |
| Hodgkin's Disease |
1.9% |
| Malignant Neoplasm Nos |
1.9% |
| Prophylaxis |
1.9% |
| Pulmonary Mass |
1.9% |
| B-cell Lymphoma Recurrent |
1.7% |
| Bronchial Carcinoma |
1.7% |
|
| Disease Progression |
13.3% |
| Encephalopathy |
8.2% |
| Sepsis |
8.2% |
| Hyponatraemia |
7.1% |
| Neutropenia |
7.1% |
| Vomiting |
6.1% |
| Febrile Neutropenia |
5.1% |
| Paranoia |
5.1% |
| Renal Failure Acute |
5.1% |
| Malaise |
4.1% |
| Neurotoxicity |
4.1% |
| Renal Failure |
4.1% |
| Thrombocytopenia |
4.1% |
| Drug Interaction |
3.1% |
| Hallucination |
3.1% |
| Partial Seizures |
3.1% |
| Tachycardia |
3.1% |
| Dyskinesia |
2.0% |
| Mania |
2.0% |
| Metabolic Encephalopathy |
2.0% |
|
| Secondary |
| Ewing's Sarcoma |
13.1% |
| Drug Use For Unknown Indication |
12.5% |
| Product Used For Unknown Indication |
9.0% |
| Sarcoma |
8.1% |
| Diffuse Large B-cell Lymphoma |
7.6% |
| Neoplasm Malignant |
7.2% |
| B-cell Lymphoma |
6.8% |
| Non-hodgkin's Lymphoma |
5.6% |
| Rhabdomyosarcoma |
5.3% |
| Bone Sarcoma |
4.4% |
| Lymphoma |
4.0% |
| Burkitt's Lymphoma |
3.6% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive Refractory |
2.0% |
| Prophylaxis |
2.0% |
| T-cell Lymphoma |
1.8% |
| Testis Cancer |
1.5% |
| Glioblastoma |
1.4% |
| Premedication |
1.4% |
| Pulmonary Mass |
1.4% |
| Teratoma |
1.4% |
|
| Encephalopathy |
22.6% |
| Febrile Neutropenia |
11.0% |
| Renal Tubular Disorder |
9.6% |
| Muscle Twitching |
8.2% |
| Pyrexia |
6.8% |
| Septic Shock |
4.1% |
| Neutropenia |
3.4% |
| Pancreatitis |
3.4% |
| Renal Failure |
3.4% |
| Renal Failure Acute |
3.4% |
| Sepsis |
3.4% |
| Weight Decreased |
3.4% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.7% |
| Cytolytic Hepatitis |
2.1% |
| Haematuria |
2.1% |
| Nephrogenic Diabetes Insipidus |
2.1% |
| Oesophagitis |
2.1% |
| Pleural Effusion |
2.1% |
| Psychomotor Skills Impaired |
2.1% |
| Pulmonary Fibrosis |
2.1% |
|
| Concomitant |
| Drug Use For Unknown Indication |
17.0% |
| Chemotherapy |
14.9% |
| Non-hodgkin's Lymphoma |
13.8% |
| Metastases To Bone |
12.8% |
| Bone Sarcoma |
5.3% |
| Breast Cancer |
5.3% |
| Rhabdomyosarcoma |
4.3% |
| T-cell Lymphoma |
4.3% |
| B-cell Lymphoma |
3.2% |
| Burkitt's Lymphoma |
3.2% |
| Prophylaxis Of Nausea And Vomiting |
3.2% |
| Vulval Neoplasm |
3.2% |
| Lymphoma |
2.1% |
| Antiemetic Supportive Care |
1.1% |
| Central Nervous System Lymphoma |
1.1% |
| Constipation |
1.1% |
| Epilepsy |
1.1% |
| Hodgkin's Disease |
1.1% |
| Pain |
1.1% |
| Vomiting |
1.1% |
|
| Thrombocytopenia |
15.2% |
| Pyrexia |
12.1% |
| Chills |
9.1% |
| Sudden Death |
9.1% |
| Vith Nerve Paralysis |
9.1% |
| Cellulitis |
3.0% |
| Cough |
3.0% |
| Demyelinating Polyneuropathy |
3.0% |
| Drug Level Below Therapeutic |
3.0% |
| Encephalopathy |
3.0% |
| Hyperthermia |
3.0% |
| Palpitations |
3.0% |
| Paraesthesia |
3.0% |
| Pulmonary Embolism |
3.0% |
| Rash |
3.0% |
| Renal Failure |
3.0% |
| Skin Necrosis |
3.0% |
| Stomatitis |
3.0% |
| Subcutaneous Nodule |
3.0% |
| Tongue Coated |
3.0% |
|
| Interacting |
| Drug Use For Unknown Indication |
43.8% |
| Nausea |
18.8% |
| Prophylaxis Of Nausea And Vomiting |
18.8% |
| Sarcoma |
18.8% |
|
| Toxic Encephalopathy |
75.0% |
| Pancytopenia |
25.0% |
|
